How To Deter Pharma Conflict Of Interests: Have FDA, CMS Grade Cost-Effectiveness
Executive Summary
JAMA editorial suggests ways to reduce conflicts of interest in industry marketing; study shows restricting pharmaceutical detailing at academic medical centers led to 1.67% mean absolute reduction in market share of detailed drugs.
You may also be interested in...
GSK Payments To Physicians Dropped 33% In 2015; Most Firms Saw Boost
Under CMS' Open Payments program, medical product manufacturers reported $7.52bn in payments and ownership and investment interests to physicians and teaching hospitals, up from $6.49bn in 2014.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.